Surgical Technique and Circulating Tumor DNA in Lung Cancer
This study is looking at how different surgical approaches affect the amount of circulating tumor DNA (ctDNA) in patients with early-stage non-small cell lung cancer (NSCLC). Specifically, it compares the "pulmonary vein-first" technique to the "pulmonary artery-first" technique during lung surgery. Both are standard ways to divide blood vessels during lung removal. Researchers want to see if one technique reduces the shedding of tumor cells during surgery, which might improve long-term outcomes. You may be able to join if you are 18 or older, have confirmed or suspected early-stage NSCLC, and are scheduled for lung surgery. The study aims to see if one surgical technique leads to lower ctDNA levels after surgery. The current recruitment status is unclear.
- Study design
- This is an interventional study planning to enroll 100 participants. Participants will be randomly assigned to one of two surgical technique groups.
- What's involved
- You would undergo either the pulmonary vein-first or pulmonary artery-first surgical procedure. Blood samples will be collected to measure ctDNA levels after surgery.
- Compensation
- Not stated in the trial record.
- Follow-up
- After surgery, participants will be followed up at specific times: day 1, day 7, days 7-28, 4 months, every 6 months for 2 years, and then every 6 months for up to 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
At a glance
Conditions
Where it's being run
4 sites across 1 statesStudy leadership
- Tyler Grenda, MD · PRINCIPAL_INVESTIGATOR · TJU
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Circulating tumor deoxyribonucleic acid (ctDNA) statusAt postoperative day 2
Stratified by surgical vascular division technique. A peripheral blood sample will be taken at the time of surgery to determine baseline ctDNA status. Following surgical resection a blood sample will be taken at specified time points (postoperative day 2; postoperative day 14) to determine ctDNA levels compared to baseline. The difference in the proportion of patients who have positive ctDNA status between those undergoing division/ligation in a "pulmonary-vein first" technique compared to a "pulmonary-artery first" technique will be estimated. The risk difference will be estimated along with a 95% confidence interval.
- Circulating tumor deoxyribonucleic acid (ctDNA) statusAt postoperative day 14
Stratified by surgical vascular division technique. A peripheral blood sample will be taken at the time of surgery to determine baseline ctDNA status. Following surgical resection a blood sample will be taken at specified time points (postoperative day 2; postoperative day 14) to determine ctDNA levels compared to baseline. The difference in the proportion of patients who have positive ctDNA status between those undergoing division/ligation in a "pulmonary-vein first" technique compared to a "pulmonary-artery first" technique will be estimated. The risk difference will be estimated along with a 95% confidence interval.